Discovery of LRE1 as a specific and allosteric inhibitor of soluble adenylyl cyclase.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Ramos-Espiritu, LavoisierKleinboelting, Silke
Navarrete, Felipe A
Alvau, Antonio
Visconti, Pablo E
Valsecchi, Federica
Starkov, Anatoly
Manfredi, Giovanni
Buck, Hannes
Adura, Carolina
Zippin, Jonathan H
van den Heuvel, Joop

Glickman, J Fraser
Steegborn, Clemens
Levin, Lonny R
Buck, Jochen
Issue Date
2016
Metadata
Show full item recordAbstract
The prototypical second messenger cAMP regulates a wide variety of physiological processes. It can simultaneously mediate diverse functions by acting locally in independently regulated microdomains. In mammalian cells, two types of adenylyl cyclase generate cAMP: G-protein-regulated transmembrane adenylyl cyclases and bicarbonate-, calcium- and ATP-regulated soluble adenylyl cyclase (sAC). Because each type of cyclase regulates distinct microdomains, methods to distinguish between them are needed to understand cAMP signaling. We developed a mass-spectrometry-based adenylyl cyclase assay, which we used to identify a new sAC-specific inhibitor, LRE1. LRE1 bound to the bicarbonate activator binding site and inhibited sAC via a unique allosteric mechanism. LRE1 prevented sAC-dependent processes in cellular and physiological systems, and it will facilitate exploration of the therapeutic potential of sAC inhibition.Citation
Discovery of LRE1 as a specific and allosteric inhibitor of soluble adenylyl cyclase. 2016, 12 (10):838-44 Nat. Chem. Biol.Affiliation
Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.Journal
Nature chemical biologyPubMed ID
27547922Type
ArticleLanguage
enISSN
1552-4469ae974a485f413a2113503eed53cd6c53
10.1038/nchembio.2151
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
Related articles
- The Soluble Adenylyl Cyclase Inhibitor LRE1 Prevents Hepatic Ischemia/Reperfusion Damage Through Improvement of Mitochondrial Function.
- Authors: Teodoro JS, Amorim JA, Machado IF, Castela AC, Steegborn C, Sinclair DA, Rolo AP, Palmeira CM
- Issue date: 2020 Jul 11
- Structure, mechanism, and regulation of soluble adenylyl cyclases - similarities and differences to transmembrane adenylyl cyclases.
- Authors: Steegborn C
- Issue date: 2014 Dec
- Bithionol Potently Inhibits Human Soluble Adenylyl Cyclase through Binding to the Allosteric Activator Site.
- Authors: Kleinboelting S, Ramos-Espiritu L, Buck H, Colis L, van den Heuvel J, Glickman JF, Levin LR, Buck J, Steegborn C
- Issue date: 2016 Apr 29
- The inhibitors of soluble adenylate cyclase 2-OHE, KH7, and bithionol compromise mitochondrial ATP production by distinct mechanisms.
- Authors: Jakobsen E, Lange SC, Andersen JV, Desler C, Kihl HF, Hohnholt MC, Stridh MH, Rasmussen LJ, Waagepetersen HS, Bak LK
- Issue date: 2018 Sep
- Pharmacological modulation of the CO(2)/HCO(3)(-)/pH-, calcium-, and ATP-sensing soluble adenylyl cyclase.
- Authors: Wiggins SV, Steegborn C, Levin LR, Buck J
- Issue date: 2018 Oct